We protect your health through science
Investigation
Viral Pathogenesis and Immunity
Research Lines
Content with Investigacion .
Hepatitis
- Diseño de métodos diagnósticos para el estudio de los virus de las hepatitis (VH) A, B, C, D, E: Diseñamos sistemas de PCR para su detección y caracterización.
- Evaluación de métodos diagnósticos de los VH. Colaboramos con empresas para estudios de sensibilidad y especificidad de equipos diagnósticos.
- Estudios de Seroprevalencia de los virus de las hepatitis.
- Epidemiología genómica de genomas completos de VHA, VHB, VHC, VHD y VHE en colaboración con el ECDC. Estudios de trazabilidad del VHE.
- Caracterización molecular de virus de las hepatitis mediante secuenciación masiva: a) VHB: mutantes de escape HBsAg (prevalencia y efectos en la detección del HBsAg). Estudio de mutaciones en epítopos de estimulación inmune y mutaciones asociadas a evolución clínica desfavorable.
- b) VHC: resistencias a los antivirales de acción directa. Análisis molecular de subtipos poco frecuentes.
c) Estudios filogenéticos del VHD.
d) Análisis genómico del VHE.
e) Investigación etiológica de hepatitis no filiadas mediante estudios de metagenómica.
- b) VHC: resistencias a los antivirales de acción directa. Análisis molecular de subtipos poco frecuentes.
Research projects
Content with Investigacion .
1. Proyecto CIBEREPS 2022. Microbiological and genomic investigation of hepatitis in children by metagenomic approach in case and control subjects (IP: Ana Avellón).
2023-2024. En colaboración con el Hospital San Joan de Deu de Barcelona.
2. MPY 501-19: Tracking hepatitis E virus infection by means of epidemiological research and whole genome sequencing. Project TrazHE. (IP: Ana Avellón). 2020-2024.
3. Proyecto CIBEREPS 2021 Metagenomic sequencing to identify viral aetiologies in undiagnosed paediatric cases of meningitis and encephalitis (IP: D. Tarragó). 2021-2022.
4. MPY 383/19 (PEJ2018-004446-A). Ayudas para la promoción de empleo joven e implantación de la garantía juvenil en I+D+I. análisis de la complejidad de secuencias de los virus de la hepatitis A, B, C; D y E (VHA, VHB, VHC, VHD y VHE) mediante técnicas de secuenciación masiva. (IP: Ana Avellón). 2020-2021.
5. MPY 1285/16 Movilidad "Salvador de Madariaga" programa estatal de promoción de talento y su empleabilidad. (IP: Ana Avellón). 2016.
Publications
Alcazar-Fuoli L, Clavaud C, Lamarre C, Aimanianda V, Seidl-Seiboth V, Mellado E, Latgé JP. Functional analysis of the fungal/plant class chitinase family in Aspergillus fumigatus.
Alcazar-Fuoli L, Clavaud C, Lamarre C, Aimanianda V, Seidl-Seiboth V, Mellado E, Latgé JP. Functional analysis of the fungal/plant class chitinase family in Aspergillus fumigatus. Fungal Genet Biol. 2011 Apr;48(4):418-29. doi: 10.1016/j.fgb.2010.12.007. Epub 2010 Dec 22. PMID: 21184840.
PUBMED DOIImpact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study.
Jiménez-Sousa MA (AC); Gómez-Moreno AZ; Pineda-Tenor D; et al. (1/9) Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. Biomolecules 2019; 9(4).
DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: a retrospective study.
Jiménez-Sousa MA (AC); Jiménez JL; Fernández-Rodríguez A; et al. (1/10). DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: a retrospective study. Journal of Biomedical Science. 2019; 23;26(1):83. doi: 10.1186/s12929-019-0577-y.
TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients.Journal of Clinical Medicine.
Resino S; Fernández-Rodríguez A; Pineda-Tenor D; et al; Jiménez-Sousa MA. (11/11). 2021. TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients.Journal of Clinical Medicine. 10-3, pp.483. ISSN 2077-0383. https://doi.org/10.3390/jcm10030483.
Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients
Salguero, Sergio; Rojo, David; Berenguer, Juan; et al; Jimenez-Sousa, Maria A. (AC) (15/15). 2020. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients LIVER INTERNATIONAL. 40-9, pp.2215-2227. ISSN 1478-3223. https://doi.org/10.1111/liv.14580 3
Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals JOURNAL OF CLINICAL MEDICINE.
Molina-Carrion, Silvia; Brochado-Kith, Oscar; Gonzalez-Garcia, Juan; et al; Jimenez-Sousa, Maria Angeles. (12/12). 2020. Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals JOURNAL OF CLINICAL MEDICINE. 9. ISSN 2077-0383. https://doi.org/10.3390/jcm9082407.
Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. Respiration. 2018 Jul
Alastruey-Izquierdo A, Cadranel J, Flick H, Godet C, Hennequin C, Hoenigl M, Kosmidis C, Lange C, Munteanu O, Page I, Salzer HJF; on behalf of CPAnet. Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. Respiration. 2018 Jul 6:1-12. doi: 10.1159/000489474. [Epub ahead of print] Review. PMID: 29982245.
PUBMED DOIThe Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. Open Forum Infect Dis. 2019 Dec
Samayoa B, Aguirre L, Bonilla O, Medina N, Lau-Bonilla D, Mercado D, Moller A, Perez JC, Alastruey-Izquierdo A, Arathoon E, Denning DW, Rodríguez-Tudela JL; “Fungired”. The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. Open Forum Infect Dis. 2019 Dec 15;7(1):ofz534. doi: 10.1093/ofid/ofz534. PMID: 31915715.
PUBMED DOIAdditional Information
The activity of this unit focuses on the development and clinical validation of point-of-care diagnostic methodology against liver viruses based on an emerging field, nanotechnology, a line of research that is developed in collaboration with BioAssays SL. Likewise, this unit focuses on delving into the immuno-virological mechanisms underlying viral infections and coinfections with other microorganisms and their influence on the host through a comprehensive approach to laboratory techniques.
One of the main lines of research involves the study of the coinfection of viral hepatitis with the Human Immunodeficiency Virus (HIV), evaluating the impact of coinfection and elimination of hepatitis C on the HIV reservoir, as well as its impact on virus-induced senescence, among others through the use of “omic” technologies.
Our group leads the Multidisciplinary HIV/Hepatitis Coinfection Group (COVIHEP), and maintains collaborations with national and international research groups of excellence, facilitating greater harmonization and quality in the biomedical research carried out. On the other hand, Dr. Briz maintains close collaboration with private companies, promoting intersectoral alliances that represent a competitive advantage.
The activity of this unit focuses on the development and clinical validation of point-of-care diagnostic methodology against liver viruses based on an emerging field, nanotechnology, a line of research that is developed in collaboration with BioAssays SL. Likewise, this unit focuses on delving into the immuno-virological mechanisms underlying viral infections and coinfections with other microorganisms and their influence on the host through a comprehensive approach to laboratory techniques.
One of the main lines of research involves the study of the coinfection of viral hepatitis with the Human Immunodeficiency Virus (HIV), evaluating the impact of coinfection and elimination of hepatitis C on the HIV reservoir, as well as its impact on virus-induced senescence, among others through the use of “omic” technologies.
Our group leads the Multidisciplinary HIV/Hepatitis Coinfection Group (COVIHEP), and maintains collaborations with national and international research groups of excellence, facilitating greater harmonization and quality in the biomedical research carried out. On the other hand, Dr. Briz maintains close collaboration with private companies, promoting intersectoral alliances that represent a competitive advantage.